- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00035412
St. John's Wort Versus Placebo in Social Phobia
Study Overview
Detailed Description
Social Phobia is a prevalent and debilitating condition, with a lifetime prevalence rate to be 13.3 percent. Socially phobic patients have been found to be functionally impaired in the areas of education, employment and social relationships, to have poorer quality of life, and increased suicidal ideation and psychiatric comorbidity. Double-blind studies have found benzodiazepines, selective and non-selective MAOI inhibitors, several SSRIs, and the anticonvulsants pregabalin and gabapentin to be effective. However, side effects with these compounds suggests the need for better tolerated compounds, e.g., in the paroxetine multi-center trial (the only drug with an FDA approved indication), 27 percent reported somnolence, 26 percent nausea, and 37 percent of males reported delayed ejaculation; 34 percent of patients discontinued the trial early. There has been considerable worldwide interest in St. John's Wort (SJW) (Hypericum perforatum) as a treatment of mild to moderate depression. There have been 23 randomized trials suggesting SJW is more effective than placebo for the treatment of outpatients with mild to moderate depression. SJW is very well tolerated with mild side effects observed in only 2.5 percent of cases in a large (3250 patients) drug monitoring study. Pharmacokinetic studies have found Hypericum to have affinity for serotonin, dopamine and GABA alpha and GABA beta receptors, each of which have been implicated in social phobia, thus there is a suggestion that SJW may be effective for this disorder.
This will be a 12-week, double blind, placebo-controlled trial, designed to generate effect size data that will be used to determine sample size needed to power a definitive study. Forty patients will be randomized to either SJW (LI 160) or matching placebo. This will be a flexible-dose design, starting at 300 mg tid to a maximum of 1800 mg total per day. An intent-to-treat analysis will be employed. Subjects will be evaluated weekly for two weeks, then bi-weekly thereafter. The primary outcome measure will be the change from baseline to endpoint on the Liebowitz Social Anxiety Scale.
Study Type
Enrollment
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53562
- The Dean Foundation for Health, Research, and Education
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female patients: at least 2 years post-menopausal, surgically sterile, or practicing a medically acceptable method of contraception.
- Meets DSM-IV criteria for Social Phobia, generalized subtype, lasting 12 months in duration (phone screening will determine)
Exclusion Criteria:
- Primary diagnosis of major depression, dysthymia, panic disorder, schizophrenia, schizo-affective disorder, bipolar disorder, or PTSD
- Substance abuse or dependence in the past 6 months
- Vascular dementia or primary degenerative dementia of the Alzheimer's type
- Treatment with MAOIs, TCAs, SSRIs, venlafaxine, nefazodone, remeron, citalopram, or bupropion within 14 days of first visit.
- Fluoxetine within 14 days of first visit.
- Failure to respond to at least two adequate antidepressant trials for social anxiety.
- Investigational drugs within 30 days of baseline
- Known allergy or hypersensitivity to St. John's Wort
- Currently in behavior therapy for Social Phobia
ALL INQUIRIES WILL UNDERGO A PHONE SCREENING TO DETERMINE WHETHER THEY MEET ELIGIBLITY REQUIREMENTS.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Collaborators and Investigators
Investigators
- Principal Investigator: Kenneth Kobak, PhD, Dean Foundation for Health, Research and Analysis
- Principal Investigator: Leslie Taylor, MD, Dean Foundation for Health, Research and Analysis
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R21AT000502-01A1 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Phobic Disorders
-
Duke UniversityBaylor College of Medicine; Yale University; Icahn School of Medicine at Mount... and other collaboratorsCompletedANXIETY DISORDERS (or Anxiety and Phobic Neuroses)United States
-
University Hospital TuebingenUnknown
-
VU University of AmsterdamCompletedPhobic DisordersNetherlands
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Southern Methodist UniversityCompletedPhobic DisordersUnited States
-
Connor, Kathryn M., M.D.Forest LaboratoriesCompleted
-
University Hospital, MontpellierLuc Nicon, Education Specialist, Founder of "Tipi", a non-profit French associationCompleted
-
Ecole Polytechnique Fédérale de LausanneUniversity Hospital, GenevaNot yet recruiting
-
Central Hospital, Nancy, FranceRecruitingClaustrophobiaFrance
-
Norwegian University of Science and TechnologySt. Olavs HospitalCompletedPhobic DisordersNorway
Clinical Trials on St. John's Wort
-
Ceres Heilmittel AGUniversity of ZurichCompleted
-
Mayo ClinicNational Cancer Institute (NCI)Completed
-
Mayo ClinicCompletedIrritable Bowel SyndromeUnited States
-
University of Southern DenmarkCompleted
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedLymphoma | Myelodysplastic Syndromes | Leukemia | Fatigue | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous ConditionUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedBreast Cancer | Hot FlashesUnited States
-
The University of QueenslandCompletedAnxiety Disorders | Depressive Disorder, MajorAustralia
-
National Center for Complementary and Integrative...CompletedObsessive Compulsive DisorderUnited States
-
Max Zeller Soehne AGCompleted
-
National Center for Complementary and Integrative...CompletedAnxiety Disorders | Mental HealthUnited States